Perimenopause Depression: Hormone Therapy, Antidepressants or Both?

For a major depressive episode during perimenopause, the expert guidelines name antidepressants and psychotherapy as the front-line treatments. Estrogen is not FDA-approved for depression, but there is evidence that it has antidepressant effects in perimenopausal women, particularly those who also have hot flashes and night sweats. Many people end up with both: an antidepressant or therapy for mood, and hormone therapy or a nonhormonal medication for hot flashes and sleep.

The right mix depends on how severe the depression is, whether you have had depression before, how much menopause symptoms are driving the problem, and whether hormone therapy is safe for you.

What the perimenopausal depression guidelines say

In 2018, an expert panel convened by the North American Menopause Society and the Women and Mood Disorders Task Force of the National Network of Depression Centers published guidelines for evaluating and treating perimenopausal depression. The society now calls itself The Menopause Society. The guidelines' main points:

• Perimenopause, which spans the early and late menopause transition and the early postmenopause, is a window of vulnerability for both depressive symptoms and major depressive episodes.
• Most midlife women who have a major depressive episode during perimenopause have had a depressive episode before.
• Depression at this stage commonly appears alongside hot flashes, night sweats, sleep disruption and midlife stresses, and these overlap and complicate the picture.
• Diagnosis should include identifying menopausal stage, assessing both psychiatric and menopause symptoms, considering other causes, and using validated screening tools.
• Proven depression treatments, antidepressants and psychotherapy, are front-line.
• Estrogen is not approved to treat perimenopausal depression, but has evidence of antidepressant effects in perimenopausal women, especially with hot flashes. Data on estrogen plus progestin are sparse and inconclusive.

These guidelines address the perimenopause specifically. They do not suggest that estrogen treats depression later in postmenopause.

How the UK's NICE menopause guideline frames it

NICE's menopause guideline, last updated in April 2026, draws a useful line between depressive symptoms and a depressive disorder. For depressive symptoms that do not meet the criteria for a diagnosis of depression and that began around the same time as other menopause symptoms, it suggests considering hormone therapy, and it suggests considering CBT for depressive symptoms that come with hot flashes and night sweats. For anyone suspected of having, or diagnosed with, depression, it says to follow the menopause guideline alongside NICE's guideline on treating depression in adults. In other words, both the US and UK guidance treat a true depressive episode as depression first, with menopause care alongside.

How a clinician works out what is going on

The 2018 guidelines ask clinicians to identify your menopausal stage as part of the evaluation. Stage is judged mainly from your cycles. Under the widely used STRAW+10 staging system, the early menopause transition is marked by a persistent difference of 7 days or more in the length of consecutive cycles, recurring within 10 cycles; the late transition is marked by a stretch of 60 days or longer without a period, and vasomotor symptoms are likely to appear in that stage.

Blood tests are less useful than many people expect. NICE advises identifying perimenopause in otherwise healthy people aged 45 or over from symptoms and cycle changes, without laboratory tests, and recommends against using tests such as estradiol, anti-Müllerian hormone or inhibin to identify perimenopause or menopause at that age. It reserves an FSH blood test for confirming menopause in people aged 40 to 45 with menopause symptoms, including a change in their cycle, or in people under 40 in whom menopause is suspected. For people aged 45 or over, the answer rests on symptoms and cycle pattern rather than on a blood result.

A good evaluation also looks beyond hormones and mood:

• Your mood history, including past depression, premenstrual mood symptoms and mood after childbirth.
• Sleep, including night sweats, snoring and early waking.
• Medical contributors such as thyroid problems or anemia, and medications that can affect mood; medical causes to rule out lists the usual checks.
• Alcohol use, which often creeps up in midlife and worsens both sleep and mood.
• A validated depression questionnaire, repeated over time; PHQ-9 and GAD-7 scores explained shows how these are read.

Bringing a few months of notes on your cycle, sleep, hot flashes and mood to the first visit makes all of this faster and more accurate.

Where hormone therapy fits

Hormone therapy is primarily a treatment for menopause symptoms. The 2022 hormone therapy position statement of the North American Menopause Society calls it the most effective treatment for vasomotor symptoms (hot flashes and night sweats) and the genitourinary syndrome of menopause, and notes it prevents bone loss and fracture. For women younger than 60 or within 10 years of menopause onset who have no contraindications, the statement finds the benefit-risk ratio favorable for bothersome hot flashes and bone protection. Starting more than 10 years after menopause or after age 60 appears less favorable, because of greater absolute risks of coronary heart disease, stroke, blood clots and dementia.

The type of hormone therapy depends on your anatomy. NICE advises offering combined hormone therapy (estrogen with a progestogen) to people with a uterus, and estrogen-only therapy to people who have had a total hysterectomy. Estrogen-only therapy raises the risk of endometrial cancer in people with a uterus, which is the reason for the progestogen, and systemic estrogen-alone products still carry an endometrial cancer boxed warning.

Risks differ by type, dose, duration, route (pill, patch, gel), timing and whether a progestogen is used, so the statement calls for individualized treatment and periodic reevaluation.

FDA labeling is also changing. In February 2026, the FDA approved labeling changes for six menopausal hormone therapy products that removed risk statements about cardiovascular disease, breast cancer and probable dementia from the boxed warning. The FDA had asked makers of all menopausal hormone therapies for these changes in November 2025, while keeping cardiovascular and breast cancer information in the labeling for systemic products and keeping the endometrial cancer boxed warning for systemic estrogen-alone products. The risks are still part of the conversation, and your own history still decides whether hormone therapy is right for you.

When hot flashes and night sweats are waking you repeatedly, treating them can improve sleep, and better sleep often helps mood. That is one reason hormone therapy can be a reasonable part of the plan even though it is not a depression treatment on its own.

Where antidepressants and therapy fit

For a clear major depressive episode, the guidelines put antidepressants and psychotherapy first. This is especially important if you have had depression before, if symptoms are moderate to severe, or if you are having thoughts of death or self-harm. How a first antidepressant is chosen is covered in SSRI, SNRI or bupropion, and the evidence for combining the two is in medication, therapy or both.

Some antidepressants also reduce hot flashes. Low-dose paroxetine (Brisdelle) is FDA-approved for moderate to severe menopausal vasomotor symptoms; its label states it is not indicated for any psychiatric condition and uses a lower dose than depression treatment does. Other antidepressants are sometimes used off-label for hot flashes. If you need treatment for both depression and hot flashes, your prescriber can consider whether one medication might address both, or whether two separate treatments make more sense.

If you already take an antidepressant

Mood can shift during perimenopause even when a long-standing antidepressant has been working. That is not a sign the medication has failed or that you did something wrong. It is a reason to see your prescriber, who may review the dose, check for other contributors such as poor sleep, thyroid changes or alcohol, and talk with you about whether menopause treatment should be part of the plan. Keep taking the antidepressant as prescribed while you sort this out.

If you are thinking about suicide or are in crisis, call or text 988 (the 988 Suicide & Crisis Lifeline) or go to the nearest emergency room.

Nonhormonal options for hot flashes

For people who cannot or prefer not to take hormones, newer nonhormonal medications target the brain's temperature-control pathway.

• Fezolinetant (Veozah) was approved by the FDA in May 2023 as the first neurokinin 3 (NK3) receptor antagonist for moderate to severe hot flashes caused by menopause. In December 2024, the FDA added a boxed warning about rare but serious liver injury, with liver blood tests recommended before starting, monthly for the first three months, and at months 6 and 9.
• Elinzanetant (Lynkuet), a neurokinin 1 and 3 receptor antagonist, is also FDA-approved for moderate to severe menopausal vasomotor symptoms. Its label calls for liver blood tests before starting and three months in, warns about drowsiness, says it must not be taken during pregnancy, and (since an August 2026 update) advises caution for anyone with a history of seizures.

These medications treat hot flashes. They are not antidepressants. If depression is present, it still needs its own treatment. For sleep problems specifically, the practice's article on non-hormonal medication options for perimenopausal insomnia goes further.

Matching the treatment to your situation

For a wider comparison of depression treatments, including neuromodulation, see depression treatment options compared.

Special situations

A history of premenstrual or postpartum mood problems

If your mood has been sensitive to hormonal shifts before, for example severe premenstrual symptoms or depression after a pregnancy, tell every clinician involved. That history helps them interpret what is happening now. The guides on PMDD treatment options and postpartum depression treatment options describe those conditions.

Breast cancer or tamoxifen

If you have had breast cancer, hormone therapy may not be advised, which shifts more weight onto antidepressants, therapy and nonhormonal hot-flash treatments. Antidepressant choice needs care here: the label for Brisdelle (low-dose paroxetine) warns that the effectiveness of tamoxifen may be reduced when the two are taken together. If you take tamoxifen or another cancer medication, make sure your oncologist and your psychiatric prescriber both review any antidepressant before you start it.

Bipolar disorder

If you have bipolar disorder, or have ever had an episode of unusually high energy and little need for sleep, a psychiatrist should be involved in any new treatment for depression, because the options and risks are different. See bipolar depression treatment options.

Anxiety and insomnia

Anxiety and broken sleep often arrive alongside low mood in perimenopause and can be treated directly. Perimenopause anxiety treatment options covers anxiety, and for sleep, the practice's article on CBT-I for menopausal insomnia explains the first-line behavioral treatment.

Pregnancy is still possible

Perimenopause is not the end of fertility. NICE advises clinicians to share information about contraception with people who have menopause symptoms, and some treatments must not be used in pregnancy, including elinzanetant. If pregnancy is possible or planned, raise it before starting anything new; psychiatric medications during pregnancy covers the mood side.

What a realistic timeline looks like

Expect weeks, not days. Antidepressants usually take 4 to 8 weeks to work, and sleep, appetite, energy and concentration often improve before mood lifts. Hormone therapy and nonhormonal hot-flash medicines have their own timelines, which your prescriber can explain.

Where possible, change one thing at a time. If an antidepressant and hormone therapy start in the same week and you feel better, or worse, nobody can tell which was responsible. A hypothetical sequence that keeps things readable: treat the most urgent problem first (a major depressive episode, or severe night sweats wrecking sleep), review progress after an agreed interval, then add or adjust the second treatment. Keep the same mood and symptom log throughout so each change can be judged against it.

Signs the plan needs a rethink

• Mood has not improved after the agreed review interval, even if hot flashes have.
• Hot flashes and sleep are better, but you still feel flat, hopeless or unable to enjoy things.
• New agitation, restlessness or unusually high energy after a medication change. Report this to the prescriber promptly.
• Side effects are making it hard to keep taking a treatment as prescribed.
• Your clinicians are giving you conflicting advice and nobody is coordinating.

Any of these is a reason to book a review rather than to change treatment on your own. If depression has not responded to a couple of adequate trials, a psychiatrist's view is worth getting; when antidepressants haven't worked explains what that evaluation looks for.

Common mistakes

• Assuming low mood is "just hormones" and waiting it out when it meets the criteria for depression.
• Assuming the opposite, that hot flashes and night sweats are irrelevant to mood.
• Relying on a single hormone blood test to confirm or rule out perimenopause.
• Starting several new treatments, supplements included, at the same time.
• Stopping an antidepressant after starting hormone therapy without the prescriber's guidance.
• Letting the gynecologist and psychiatrist work from different medication lists.

Psychiatrist, gynecologist, or both

A gynecologist or menopause-trained primary care clinician is usually the right person to evaluate and prescribe hormone therapy, review contraindications and manage bleeding changes. A psychiatrist is the right person when depression is moderate or severe, when you have a history of depression, bipolar disorder or anxiety disorders, when one or two antidepressants have not helped, or when you already take several psychiatric medications.

The two specialties look at the same symptoms from different angles. A gynecologist may see irritability and poor sleep as part of the menopause transition; a psychiatrist may see the start of a depressive episode. Both can be right, which is why a shared picture matters more than which door you walk through first.

It also helps to give each clinician the information the other one usually collects. Tell your gynecologist about past depression, current mood and any psychiatric medications; tell your psychiatrist about your cycle changes, hot flashes, any hormonal contraception or hormone therapy, and relevant history such as clotting problems or cancer. A one-page summary you update and bring to every appointment is often the simplest way to do this, and it saves time at each visit. If one clinician recommends something the other is unsure about, ask them to speak directly rather than relaying the disagreement yourself.

Many people need both, and the plan is safer and clearer when the two talk. Practical steps:

1. Sign releases so your gynecologist and psychiatrist can share notes.
2. Keep one current list of every hormone, medication and supplement, and give it to both.
3. Track mood, sleep, hot flashes and cycle changes together, so both clinicians see the same pattern.
4. Agree on who adjusts what, so two changes do not happen at once.
5. Do not stop an antidepressant because you have started hormones, or the reverse, without talking to the prescriber.

What to look for in a psychiatrist for this stage of life is covered in choosing a perimenopause-informed psychiatrist in NYC, and early signs are in signs you're in perimenopause. If you are deciding who should prescribe your antidepressant, see psychiatrist or primary care. More guides are in the choosing psychiatric care guide.

Questions to bring to your appointments

• Is this a major depressive episode, menopause symptoms, or both, and how did you decide?
• Given my history, is hormone therapy an option for me? Which type, dose and route would you suggest, and why?
• If I start hormone therapy, how will we tell whether my mood is improving because of it?
• Would one medication help both my mood and my hot flashes, or do I need two treatments?
• What monitoring does each medication need, including liver tests if I take fezolinetant or elinzanetant?
• Who should I call first if my mood gets worse?

Write down the answers, or ask for them in your visit summary. Sharing that summary with your other clinicians keeps everyone working from the same plan.

How this practice handles it

The practice's ongoing care includes psychiatric evaluation and medication management, psychotherapy, coaching, lab testing, and nutrition and lifestyle psychiatry. The 75-minute Health Strategy Session with Dr. Lewis reviews health history and top concerns, explores treatment options, and can include a discussion of comprehensive bloodwork and functional medicine testing if appropriate. The practice's page on perimenopause psychiatry in NYC describes its approach, and care starts with a free discovery call.

Frequently asked questions

Can hormone therapy replace my antidepressant?

Not on its own say-so. Estrogen is not FDA-approved for depression. Some people on both later reduce an antidepressant under supervision, but that decision belongs with your prescriber, made gradually and with a plan if symptoms return.

Is it perimenopause or depression?

It can be both. The 2018 guidelines note that menopause symptoms and depression overlap and often occur together, so a good evaluation looks at mood, sleep, hot flashes, menstrual changes and life stresses at the same time.

Should I see my gynecologist or a psychiatrist first?

If depression is severe, you have thoughts of self-harm, or you have a history of depression or bipolar disorder, start with psychiatric care. If hot flashes and sleep disruption are the main problem and mood symptoms are mild, your gynecologist is a reasonable first stop. Many people need both.

Can therapy alone help perimenopausal depression?

Psychotherapy is one of the front-line treatments named in the 2018 guidelines. Whether therapy alone is enough depends on severity and your history; a clinician can help you decide and check progress.

Does fezolinetant help depression?

It is approved to treat moderate to severe hot flashes caused by menopause, not depression. Better sleep from fewer night sweats may help how you feel, but depression still needs its own treatment.

Do I need a blood test to know whether I am in perimenopause?

Usually not. NICE advises identifying perimenopause in otherwise healthy people aged 45 or over from symptoms and cycle changes, without laboratory tests. Testing has a narrower role, mainly in people under 45.

Can I take hormone therapy and an antidepressant at the same time?

Many treatment plans include both, one for mood and one for menopause symptoms. Make sure each prescriber knows everything you take so they can check for interactions, and agree on which change happens first so the effect of each can be judged.

Sources

1. Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. Menopause (Maki PM et al.; NAMS Board of Trustees and Women and Mood Disorders Task Force of the National Network of Depression Centers), 2018. pubmed.ncbi.nlm.nih.gov
2. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause (NAMS Advisory Panel), 2022. pubmed.ncbi.nlm.nih.gov
3. FDA Approves Novel Drug to Treat Moderate to Severe Hot Flashes Caused by Menopause. U.S. Food and Drug Administration, 2023. fda.gov
4. FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause. U.S. Food and Drug Administration (Drug Safety Communication), 2024. fda.gov
5. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. U.S. Food and Drug Administration, 2026. fda.gov
6. BRISDELLE (paroxetine) capsules prescribing information. U.S. Food and Drug Administration / DailyMed, 2025. dailymed.nlm.nih.gov
7. LYNKUET (elinzanetant) prescribing information. U.S. Food and Drug Administration / DailyMed, 2026. dailymed.nlm.nih.gov
8. The Menopause Society. The Menopause Society, 2026. menopause.org
9. FDA Requests Labeling Changes Related to Safety Information to Clarify the Benefit/Risk Considerations for Menopausal Hormone Therapies. U.S. Food and Drug Administration, 2025. fda.gov
10. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause (Harlow SD et al.; STRAW+10 Collaborative Group), 19(4):387-95, 2012. pmc.ncbi.nlm.nih.gov
11. Menopause: identification and management (NG23), Recommendations. National Institute for Health and Care Excellence, 2026. nice.org.uk
12. Mental Health Medications. National Institute of Mental Health, 2026. nimh.nih.gov

Educational information, not medical, tax or legal advice. Decisions about diagnosis, medication and treatment belong with a clinician who knows your history.